Movement Disorders

Aldo Quattrone, Maurizio Morelli, Basilio Vescio, Salvatore Nigro, Emilio Le Piane, Umberto Sabatini, Manuela Caracciolo, Virginia Vescio, Andrea Quattrone, Gaetano Barbagallo, Carlo Stanà, Giuseppe Nicoletti, Gennarina Arabia, Rita Nisticò, Fabiana Novellino, Maria Salsone February 14, 2019

ABSTRACT

Background

No prospective study of patients with Parkinson’s disease (PD) has investigated the appearance of vertical gaze abnormalities, a feature suggestive of progressive supranuclear palsy (PSP).

Objective

To identify, within a cohort of patients with an initial diagnosis of PD, those who developed vertical gaze abnormalities during a 4‐year follow‐up, and to investigate the performance of new imaging biomarkers in predicting vertical gaze abnormalities.… Read More...

Anette Schrag, Zacharias Anastasiou, Gareth Ambler, Alastair Noyce, Kate Walters February 9, 2019

ABSTRACT

Background

Diagnosis of Parkinson’s disease (PD) is typically preceded by nonspecific presentations in primary care.

Objectives

The objective of this study was to develop and validate a prediction model for diagnosis of PD based on presentations in primary care.

Setting

The settings were general practices providing data for The Health Improvement Network UK primary care database.… Read More...

Dorothee Kübler, Tobias Wächter, Nicole Cabanel, Zhangjie Su, Federico E. Turkheimer, Richard Dodel, David J. Brooks, Wolfgang H. Oertel, Alexander Gerhard February 7, 2019

Abstract

Background

The pattern and role of microglial activation in multiple system atrophy is largely unclear. The objective of this study was to use [11C](R)‐PK11195 PET to determine the extent and correlation of activated microglia with clinical parameters in MSA patients.… Read More...

Farwa Ali, Peter R. Martin, Hugo Botha, J. Eric Ahlskog, James H. Bower, Joseph Y. Masumoto, Demetrius Maraganore, Anhar Hassan, Scott Eggers, Bradley F. Boeve, David S. Knopman, Daniel Drubach, Ronald C. Petersen, Erika Driver Dunkley, Jay Gerpen, Ryan Uitti, Jennifer L. Whitwell, Dennis W. Dickson, Keith A. Josephs February 7, 2019

Abstract

Background

In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times.… Read More...

Tamara Perez‐Rosello, Simon Gelman, Geoffrey Tombaugh, Roger Cachope, Vahri Beaumont, D. James Surmeier February 7, 2019

ABSTRACT

Background

Huntington’s disease (HD) is caused by a CAG repeat expansion in the huntingtin gene. This mutation leads to progressive dysfunction that is largely attributable to dysfunction of the striatum. The earliest signs of striatal pathology in HD are found in indirect pathway gamma‐Aminobutyric acid (GABA)‐ergic spiny projection neurons that innervate the external segment of the globus pallidus (GPe).… Read More...

Daniel Ysselstein, Joshua M. Shulman, Dimitri Krainc February 7, 2019

ABSTRACT

Lysosomal storage disorders comprise a clinically heterogeneous group of autosomal‐recessive or X‐linked genetic syndromes caused by disruption of lysosomal biogenesis or function resulting in accumulation of nondegraded substrates. Although lysosomal storage disorders are diagnosed predominantly in children, many show variable expressivity with clinical presentations possible later in life.… Read More...

Haidar S. Dafsari, Pablo Martinez‐Martin, Alexandra Rizos, Maja Trost, Maria Gabriela Santos Ghilardi, Prashanth Reddy, Anna Sauerbier, Jan Niklas Petry‐Schmelzer, Milica Kramberger, Robbert W. K. Borgemeester, Michael T. Barbe, Keyoumars Ashkan, Monty Silverdale, Julian Evans, Per Odin, Erich Talamoni Fonoff, Gereon R. Fink, Tove Henriksen, Georg Ebersbach, Zvezdan Pirtošek, Veerle Visser‐Vandewalle, Angelo Antonini, Lars Timmermann, K. Ray Chaudhuri, on behalf of EUROPAR and the International Parkinson and Movement Disorders Society Non‐Motor Parkinson's Disease Study Group February 5, 2019

Abstract

Objective

Real‐life observational report of clinical efficacy of bilateral subthalamic stimulation (STN‐DBS), apomorphine (APO), and intrajejunal levodopa infusion (IJLI) on quality of life, motor, and nonmotor symptoms (NMS) in Parkinson’s disease (PD).

Methods

In this prospective, multicenter, international, real‐life cohort observation study of 173 PD patients undergoing STN‐DBS (n = 101), IJLI (n = 33), or APO (n = 39) were followed‐up using PDQuestionnaire‐8, NMSScale (NMSS), Unified PD Rating Scale (UPDRS)‐III, UPDRS‐IV, and levodopa equivalent daily dose (LEDD) before and 6 months after intervention.… Read More...

Andoird App
Loading...